Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Last trade $27.89
Day change -$1.87 (-6.28%)
Day range $27.12 – $30.05
Volume 254,281
Market cap $1.32B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.32B
Price / earnings
—
Price / book
3.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-10.18×

Profitability

Earnings per share
-$2.45
Return on assets
-27.31%
Return on equity
-29.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.04×
Current ratio
25.76×
Quick ratio
25.76×
Cash ratio
11.23×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$100.29M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AVLN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$7.6M$6.56M
Research and development$25.49M$24.73M
Total operating expenses$33.09M$31.29M
Operating income-$33.09M-$31.29M
Interest expense-$277K-$272K
Income before taxes-$29.66M-$28.94M
Income taxes$0$0
Net income-$29.66M-$28.94M
Net income attributable to common shareholders-$29.66M-$28.94M
EBITDA-$32.99M-$31.18M
Basic earnings per share-$0.67-$0.98
Diluted earnings per share-$0.67-$0.98

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Avalyn Pharma announced two poster presentations at the European Respiratory Society International Congress 2026 in Barcelona. The presentations will cover patient perspectives on IPF clinical trial participation and in silico modeling of AP01, the company's nebulized pirfenidone formulation. Avalyn has completed enrollment of its Phase 2b MIST trial with 398 patients, with topline data expected in the second half of 2027.

GlobeNewswire Inc.

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Avalyn Pharma announced completion of target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis. The global, randomized, double-blinded, placebo-controlled trial is evaluating two doses of AP01 against placebo, with primary endpoint measuring change in lung function at 52 weeks. Topline data is expected in the second half of 2027.

GlobeNewswire Inc.

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma, a clinical-stage biopharmaceutical company, announced Q1 2026 financial results and pipeline updates following its May 2026 IPO that raised $345 million in gross proceeds. The company is on track to complete enrollment of its MIST Phase 2b trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis by mid-2026, with topline data expected in H2 2027. Long-term open-label extension data presented at EULAR showed favorable tolerability over four years. AP02 (inhaled nintedanib) enrollment is underway in the AURA Phase 2 trial with results anticipated by end of 2027. The company projects its cash position of $123.1 million plus $316.1 million in IPO proceeds will fund operations into 2029.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 25, 20071-for-3reverse split